NCT03415763 - Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy | Biotech Hunter

Enrollment

764

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions

Rectal Neoplasms

Interventions

DRUG

Capecitabine

According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.

DRUG

mFOLFOX6 or CAPOX

According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai